Education

Doctor degree in Medical genomics from Jilin University, postdoctoral fellow from Peking University, Senior visiting scholar at University of Southern California.

 

Academic Experience

Since June 2010, Wenzhou Medical University.

 

Overview of Academic Research

Innovative drug design and mechanism analysis of cell growth factor.

1: Research on protein drug delivery system.

2: Molecular mechanism of tissue regeneration and organ remodeling.

3: Molecular diagnosis of cell growth factor.

 

Major Honor and Awards

Ø Second Prize of National Science and Technology Progress Award (2018), First Prize of Natural Science Award of the Ministry of Education (2017), First Prize of Natural Science Award of Zhejiang Province (2020).

Ø National First Prize for Educational Achievement (2023), Huang Dayan-style Teaching Team of Pharmacy (2022), National May 1st Labor Medal (2021), Special Prize for Teaching Achievements in Zhejiang Province (2022), Outstanding Teacher in Zhejiang Province (2022), and Tier 1 Talent in the "151 Talent Project" of Zhejiang Province.

(1)National Natural Science Foundation general project，"Targeted Delivery of FGF10 mRNA via Human Lung Spheroid Cell-Derived Exosomes for the Treatment of Idiopathic Pulmonary Fibrosis Study(82470066)",2025.01-2028.12,head.

(2) Major Special Project of the Ministry of Science and Technology, "Industrialization Research of Recombinant Human keratinocyte Growth Factor-2 for a Class of New Drugs (2016ZX09101117)", RMB 8.6496 million, 2016.1-2019.12, head.

(3) National Natural Science Foundation of China, "Research on KGF-2 Inhibiting Mechanical Stress-Mediated Hypertrophic Scar by Regulating STAT3 Phosphorylation through IL6 Reverse Signaling (81971843)", 2020.01-2023.12, RMB 0.55 million, head.

(4)"Spearhead" and "Leading goose" research project of Zhejiang Province, "Preclinical Research of recombinant Human KGF-2, a new drug targeting the cause of dry eye Disease (2022C03110)", 2022.1-2024.12, RMB 1 million, head.

(5) Cooperative Development with China Resources Zizhu Pharmaceutiacl Co., Ltd., "KGF-2 Eye Drops (Dry Eye Disease) Project (20230920G0821)", 2023.9-2025.12, RMB 17 million, head.

(6) Major Project of Wenzhou, "Phase I Clinical Study of a New Class of Drug: Recombinant Human Keratinocyte Growth Factor-2 Eye Drops for the Treatment of Diabetic Keratopathy (2022C03110)", 2020.1-2022.12, RMB 1.6 million, head.

 

Representative Research Achievements

1.Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2. Nat Commun, 2024,5(1):2236Corresponding （IF14.7, JCRQ1, TOP）

2.Injection of ROS-Responsive Hydrogel Loaded with Basic Fibroblast Growth Factor into the Pericardial Cavity for Heart Repair. Adv Funct Mater, 2022, 31 (15) 2021 Corresponding (IF19.9, JCRQ1, TOP)

3. Modified poloxamer 407 and hyaluronic acid thermosensitive hydrogel-encapsulated keratinocyte growth factor 2 improves knee osteoarthritis in rats. Materials and Design, 2021, 210(15): 110086. Corresponding （IF 9.4, JCRQ1, TOP）

4. KGF-2 Regulates STAP-2-Mediated Signal Transducer and Activator of Transcription 3 Signaling and Reduces Skin Scar Formation. J Invest Dermatol, 2022,142 (7) Corresponding  (IF 6.5, JCRQ1, TOP)

5. Scarless Wound Healing: Current Insights From the Perspectives Of TGF-β, KGF-1, and KGF-2. Cytokine & Growth Factor Reviews, 2022, 66: 26-37. Corresponding (IF 13, JCRQ1, TOP)

6.Temperature-Enhanced Purine Metabolism-Based Versatile SERS Platform for Rapid Clinical Pathogens Diagnosis and Drug-Resistant Assessment. ANALYTICAL CHEMISTRY, 2025, 97(5):2754-2761.Corresponding (IF 6.6，JCRQ1, TOP)